Syndax Pharmaceuticals

SNDXApproved

Syndax Pharmaceuticals is a public biotech company pioneering novel cancer treatments by targeting key biological pathways, including the menin-KMT2A interaction and CSF-1R signaling. Its most advanced assets, revumenib and axatilimab, are in late-stage development for acute leukemias and chronic graft-versus-host disease, respectively, representing significant market opportunities. The company leverages a deep understanding of transcriptional regulation and the tumor microenvironment to develop differentiated therapies for patients with limited treatment options.

Market Cap

$2.1B

Employees

100-250

Focus

Biotech

SNDX · Stock Price

USD 24.23+6.63 (+37.67%)

Historical price data

AI Company Overview

Technology Platform

Focuses on developing small molecule inhibitors and monoclonal antibodies targeting key epigenetic regulators (menin) and immune modulators (CSF-1R) to treat cancer and fibrotic diseases.

Pipeline Snapshot

37 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
Revumenib + Placebo + Intensive Chemotherapy Regimen	Acute Myeloid Leukemias	Phase 3
Entinostat + Interleukin-2	Renal Cell Carcinoma	Phase 2
entinostat + anastrozole	Estrogen Receptor-negative Breast Cancer	Phase 2
Axatilimab	Idiopathic Pulmonary Fibrosis	Phase 2
Entinostat	Hodgkin's Lymphoma	Phase 2

Funding History

Total raised: $275M

PIPE$175MRA Capital ManagementFeb 15, 2021

IPO$60MUndisclosedJan 28, 2016

Series A$40MUndisclosedJun 15, 2005

FDA Approved Drugs

REVUFORJNDANov 15, 2024

Opportunities

Syndax's primary growth opportunity lies in successfully commercializing revumenib for acute leukemias and axatilimab for cGVHD, both representing multi-billion dollar markets.

Further opportunities include label expansion for these assets into earlier lines of therapy, combination regimens, and additional indications like IPF for axatilimab.

Risk Factors

Key risks include clinical trial failure of lead assets, regulatory setbacks, intense competition in target markets, and the challenge of building a commercial organization from scratch.

The company's financial sustainability depends entirely on successful clinical and regulatory outcomes.

Competitive Landscape

Revumenib faces competition from other menin inhibitors in development (e.g., Kura Oncology). Axatilimab competes with approved JAK and BTK inhibitors in cGVHD. Syndax differentiates through first-in-class mechanisms, strong clinical data positioning, and a focused development strategy in high-need patient populations.

Publications

Patents

Pipeline

FDA Approvals